2025.03.05
SUCCESSFULLY COMPLETION OF THE FIRST TWO···
This announcement is made by Peijia Medical Limited (the “ Company”, together with itssubsidiaries, ···
2025.02.10
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY ···
The team led by Academician Ge Junbo from Zhongshan Hospitalaffiliated with Fudan University, includ···
2024.11.28
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SU···
In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-developedtranscathet···
2024.11.26
PCR London Valves : HighLife® TSMVR SYST···
According to the clinical results, HighLife® achieved atechnical success rate of 89%. At 1 year, the···
2024.11.06
THE LATEST PROGRESS IN THE FIM STUDY OF ···
Since the first implantation in November 2023, a total
of 9 patients have been enrolled in MonarQ™ ···
2024.11.05
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® ···
Two-year clinical data of the HighLife® TSMVR
technology's feasibility trial involving 30 cases···
2024.11.04
SmartWave LITHOTRIPSY VALVULOPLASTY TECH···
In the trial exploring the effectiveness and safety of
using the SmartWave lithotripsy valvuloplast···
2024.11.01
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF ···
At 2 years, the cardiac mortality rate was still lower
than the study’s prespecified performance go···
2024.10.31
INTERPRETATION OF PRE-MARKET CLINICAL DA···
During October 24-27, 2024, the pre-market
clinical data for the YonFlow® flow diverter was
offici···
2024.09.27
PROFESSOR WANG YANS TEAM AT XIAMEN UNIVE···
On September 24, 2024, led by President Wang Yan
of Xiamen University Affiliated Cardiovascular
Ho···
2024.09.24
REGISTERED CLINICAL DATA OF TaurusElite®···
During September 20-22, 2024, Peijia presented multiple
clinical data at the PCR-CIT China Chengdu ···
2024.08.15
PEIJIA MEDICAL RECEIVES THE NMPA APPROVA···
Peijia Medical received the NMPA approval for the registration application of TaurusMax™ in August 1···
